diffuse large B-cell lymphoma of the central nervous system
Also known as CNS DLBCL, DLBCL of the CNS, central nervous system diffuse large B-cell lymphoma, diffuse large B-cell lymphoma of central nervous system+2 more
CNS DLBCL, DLBCL of the CNS, central nervous system diffuse large B-cell lymphoma, diffuse large B-cell lymphoma of central nervous system, primary DLBCL of the CNS, primary diffuse large B-cell lymphoma of the central nervous system.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q2 2027.
Clinical MilestonesViewHide
- 2026-05-12A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell LymphomasResults posted
- 2026-01-08Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemResults posted
- 2026-08-10ClinicalPhase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS LymphomaResults expected Q2 2027
- 2026-05-12ClinicalA Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell LymphomasResults posted
- 2026-01-08ClinicalPhase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemResults posted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or… (2024)
Approval — Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or… (2023)
Approval — Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of… (2023)
Approval — Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymph… (2022)
Approval — Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or… (2022)
Approval — Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for… (2021)
Approval — Polivy in combination with bendamustine and rituximab is indicated for the treatment of a… (2020)
Approval — Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to an… (2018)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
CNS DLBCL, DLBCL of the CNS, central nervous system diffuse large B-cell lymphoma, diffuse large B-cell lymphoma of central nervous system, primary DLBCL of the CNS, primary diffuse large B-cell lymphoma of the central nervous system
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.